Valerian: Benefits, Forms, Dosing, and Side Effects

Valerian (Valeriana officinalis) is a perennial herb native to Europe and temperate regions of Asia, whose roots and rhizomes have been used as a sedative and anxiolytic for over 2,000 years. Hippocrates described its therapeutic properties in the 5th century BCE, Dioscorides recommended it for sleep disturbances in the 1st century CE, and Galen prescribed valerian for insomnia in the 2nd century [1][2][3][4][5]. During medieval Europe, valerian earned the name "All-Heal" for its broad application in treating ailments ranging from plague symptoms to nervous disorders [6][7]. During World War II, it was distributed in England to help civilians cope with the stress of air raids [9].

The evidence for valerian's efficacy is mixed. While some clinical trials show modest improvements in subjective sleep quality and sleep latency, systematic reviews and meta-analyses generally conclude that the evidence is inconclusive for objective sleep parameters [15][16][17]. Despite these uncertainties, valerian's favorable safety profile has sustained its popularity as a gentle alternative to pharmaceutical sedatives [10][18]. This article synthesizes all available clinical and preclinical evidence for valerian, including every published trial from ConsumerLab, NIH, and Grokipedia sources.

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• Mechanisms of Action
• References

Overview

Valerian (Valeriana officinalis) is a perennial herb native to Europe and temperate regions of Asia. The genus Valeriana includes over 250 species, but V. officinalis is the species most commonly used in supplements and the focus of nearly all clinical research [2][11]. Other names include setwall (English), Valerianae radix (Latin), Baldrianwurzel (German), and phu (Greek) [11].

In the United States, valerian is sold as a dietary supplement and holds Generally Recognized as Safe (GRAS) status from the FDA for use as a flavoring agent and dietary supplement ingredient, but it is not approved as a prescription drug for any medical condition [10][11]. Dietary supplements are regulated as foods, not drugs, so premarket evaluation and approval by the FDA are not required unless specific disease prevention or treatment claims are made [11]. Because dietary supplements are not always tested for manufacturing consistency, the composition may vary considerably between manufacturing lots [11].

The plant's therapeutic effects are attributed to a complex mixture of bioactive compounds concentrated in the roots, including valerenic acids (sesquiterpenoids), valepotriates (iridoid esters), volatile oils, alkaloids, and flavonoids. No single active compound has been definitively identified as responsible for valerian's effects; rather, the activity likely results from multiple constituents acting independently or synergistically [12][13][14].

Forms and Bioavailability

Active Compounds

Valerian root contains several classes of bioactive compounds, with varying concentrations depending on plant genetics, growing conditions, harvest timing, and extraction methods [12][19][20]:

Valerenic acids are the most pharmacologically studied constituents and include three primary forms. Valerenic acid (VA) is the principal sesquiterpenoid, shown to modulate GABA-A receptors in the brain, producing anxiolytic effects [21][22]. VA acts as a subunit-specific allosteric modulator, potentiating GABA-A receptors containing beta-2 or beta-3 subunits, potentially binding near the loreclezole site [22]. Acetoxyvalerenic acid (AVA) may actually block the anxiolytic effect of VA in some models [23]. Hydroxyvalerenic acid (HVA) is formed by degradation of AVA and may enhance the activity of valerenic acid [23].

Good-quality valerian root powders contain at least 0.1% valerenic acids, while powdered extracts are typically standardized to 0.4-0.8% valerenic acids [10]. The European Pharmacopoeia mandates a minimum of 0.17% sesquiterpenic acids (expressed as valerenic acid) in cut root material, alongside at least 0.5 mL/kg essential oil content [20][24].

Valepotriates (valtrate, isovaltrate, and didrovaltrate) constitute 0.1-2% of the dry root weight [19]. These iridoid esters are unstable and degrade rapidly during storage, aqueous extraction, or exposure to heat, light, or acidic conditions, with losses of up to 50% within months [20][24]. Their breakdown product, baldrinal, is a cytotoxic aldehyde [19]. Their instability makes it difficult to assess their contribution to clinical effects; they may not be present in significant amounts in many commercial preparations [12][13].

Volatile oils (0.2-1% of root material) contribute to valerian's characteristic strong, musty odor and include sesquiterpenoids such as valeranone (0.5-18% of the oil) and esters like bornyl isovalerate (0.2-2% of the oil) [25][26].

Other constituents include alkaloids (e.g., chatinine at trace levels up to 0.05%), flavonoids including hesperidin, and GABA itself — though whether exogenous GABA from valerian extracts crosses the blood-brain barrier is uncertain [25][27][28]. Glutamine, present in aqueous but not alcohol extracts, may cross the blood-brain barrier and be converted to GABA [28]. Gas chromatography-mass spectrometry (GC-MS) profiling has identified over 100 compounds in root extracts [29].

Supplement Forms

Form	Description	Typical Dose	Valerenic Acid Content
Standardized extract (capsules/tablets)	Concentrated root extract, often ethanol- or water-extracted	300-900 mg	0.4-0.8% (standardized)
Root powder (capsules)	Dried, ground root in capsules	2,000-3,000 mg	~0.1% (variable)
Tincture	Alcohol-based extract, typically 1:5 ratio with 60-80% ethanol	4-5 mL	Variable
Tea	Dried root steeped in hot water (2-3 g per cup, 10-15 min)	2,000-3,000 mg dried root	Variable; often low
Combination products	Valerian combined with hops, lemon balm, or other herbs	Varies by product	Varies

Standardized extracts are the most commonly studied form in clinical trials and provide the most consistent valerenic acid content. Many clinical trials have used LI 156 (Sedonium), a standardized commercial preparation of dried valerian root extract [30][31][33]. Many extracts are standardized to 0.8% valerenic acids, with common potencies delivering 450 mg of total extract per dose [24].

Root powder products require higher doses (2-3 grams) to achieve equivalent valerenic acid levels compared to concentrated extracts. Root powder products may provide greater amounts of contaminants, such as lead [10].

Teas are unpredictable in valerenic acid delivery. An analysis of three valerian root teas purchased in Canada found that only one provided more than 2 mg of valerenic acids per cup (made with 2-3 grams of dried root), while the other two provided only 0.14-0.645 mg per cup (Lefebvre, J Pharm Pharmaceut Sci, 2004) [34].

Combination products containing valerian with hops, lemon balm, or other herbs are widely available. Unless the specific combination has been clinically tested, it is difficult to know whether such products are effective [10].

Bioavailability and Quality Considerations

Valerenic acid content varies significantly among plants depending on when they are harvested. Sesquiterpenic acids (including valerenic acid) peak in roots harvested from second-year or older plants, when concentrations can reach approximately 1.2% [35]. Valepotriates peak in autumn-harvested roots at the end of the first growing year [35]. Harvesting in late autumn, post-frost, maximizes root biomass and bioactive yields [36].

Extraction methods matter significantly. Solvent extraction commonly employs 60-80% ethanol (v/v), with maceration for 2-4 weeks at room temperature [20][39]. Supercritical CO2 extraction (10-40 MPa, 40-60 degrees C) produces purer essential oils with up to 95% recovery of target sesquiterpenes while avoiding residual solvents [40]. Ultrasound-assisted extraction can reduce maceration time from weeks to hours while maintaining comparable yields [40].

Quality control remains a challenge due to potential adulteration with related species. HPLC analysis of marker compounds like valerenic acids is the primary method for detecting adulterants and confirming product authenticity [37][38].

Evidence for Benefits

Sleep and Insomnia

Valerian is most commonly used as a sleep aid, although the clinical evidence remains mixed. Several systematic reviews have concluded that the overall evidence for valerian's sleep-promoting effects is inconclusive, while individual trials show varying degrees of benefit.

Systematic Reviews and Meta-Analyses

Taibi et al., 2007: A systematic review concluded that conventional valerian extracts are "probably not effective for treating insomnia" [15]. This remains one of the most cited assessments of the valerian evidence base.

Stevinson and Ernst, 2000: Evaluated nine randomized, placebo-controlled, double-blind clinical trials and concluded they were not sufficient for determining the effectiveness of valerian for sleep disorders [16]. None of the studies checked the success of blinding, none calculated the sample size necessary for detecting a statistical effect, only one partially controlled pre-bedtime variables [30], and only one validated outcome measures [42].

Bent et al., 2006: A systematic review and meta-analysis of 16 RCTs found that valerian may modestly improve subjective sleep quality — such as reduced sleep latency and enhanced feelings of refreshment — though objective measures like polysomnography showed inconsistent results [17].

Shinjyo et al., 2020: Indicated that valerian appears more effective for chronic insomnia than acute episodes, with some trials reporting improvements in sleep efficiency among participants with mild sleep disturbances [43].

2024 umbrella review: An umbrella review of eight systematic reviews involving over 15,000 participants concluded there was no evidence of benefit for objective sleep parameters such as total sleep time or number of awakenings, while noting a favorable safety profile [44].

Individual Clinical Trials

Leathwood et al., 1982 (n=128): In a repeated-measures design, 128 volunteers were given 400 mg of an aqueous valerian extract, a commercial preparation containing 60 mg valerian and 30 mg hops, and placebo on nine nonconsecutive nights in random order [42]. The valerian extract produced statistically significant subjective improvements in time to fall asleep, sleep quality, and number of nighttime awakenings. The effect was more pronounced in a subgroup of 61 self-identified poor sleepers. The valerian-hops combination did not produce significant improvements. Limitations: insomnia was not required for participation, and the study had a 22.9% withdrawal rate.

Leathwood and Chauffard, 1985 (n=8): Eight volunteers with mild insomnia received 450 mg or 900 mg of aqueous valerian extract and placebo, evaluated using wrist-worn activity meters [45]. The 450 mg dose reduced average sleep latency from about 16 to 9 minutes, similar to benzodiazepine medication. On a 9-point scale, participants rated sleep latency as 4.3 after valerian versus 4.9 after placebo. The 900 mg dose did not further reduce sleep latency and increased next-morning sleepiness. The 7-minute reduction may not be clinically significant, and the small sample size limits generalizability.

Vorbach et al., 1996 (n=121): A 28-day RCT in which 121 participants with documented nonorganic insomnia received 600 mg of standardized valerian root extract (LI 156, Sedonium) or placebo [30]. The valerian group showed decreased insomnia symptoms on all assessment tools. Notably, improvements continued to increase between day 14 and day 28, suggesting benefits develop gradually with continued use.

Dorn, 2000 (n=75): Compared 600 mg valerian extract (LI 156) with 10 mg oxazepam (a benzodiazepine) over 28 days [31]. Both groups showed equal improvement in sleep quality, but the valerian group reported fewer side effects. The study was designed to test superiority, not equivalence, so results cannot be used to claim the two treatments are equally effective.

Donath et al., 2000 (n=16, polysomnography): A crossover study using polysomnographic techniques in 16 participants with nonorganic insomnia evaluated single-dose and 14-day administration of 600 mg valerian extract (LI 156) versus placebo [33]. Valerian had no effect on 14 of 15 objective or subjective measurements. The single positive finding was decreased slow-wave sleep onset latency (13.5 min for valerian vs. 21.3 min for placebo). Slow-wave sleep is the deepest non-REM stage. Because only 1 of 15 endpoints was positive, chance cannot be excluded.

Shekhar et al., 2023 (n=72): Among 72 men and women (average age 34) with mild to moderate sleep difficulty, 200 mg of valerian root powder extract standardized to 2% valerenic acid (4 mg valerenic acid per nightly dose) taken one hour before bedtime for two months significantly decreased sleep latency by 36 minutes and increased total sleep time by 11 minutes compared to placebo [46]. However, sleep quality improvement was only slight versus placebo. The study was funded by the extract manufacturer (OmniActive Health Technologies).

Shekhar et al., 2024 (follow-up): A subsequent analysis showed the longer sleep time occurred on the first night, although there were no improvements that night in time to fall asleep or sleep quality [47].

Bliwise et al., 2007 (Parkinson's disease): Failed to show benefit overall in Parkinson's disease patients, who often have sleep disturbances. Further analyses suggested a possible benefit in male participants [48]. Many conventional sedative-hypnotic drugs also fail in Parkinson's patients.

Taavoni et al., 2011 (postmenopausal women): Among postmenopausal women aged 50-60 with insomnia, 530 mg of valerian root extract (standardized to 0.5-1% valerenic acids) twice daily for 4 weeks produced sleep improvement in 30% of participants versus 4% in the placebo group [49]. No adverse events were reported.

Synthesis: Valerian may modestly improve subjective sleep quality in some populations, particularly in individuals with mild to moderate chronic insomnia. Effects appear to develop gradually over 2-4 weeks. Objective polysomnographic evidence is weak and inconsistent. Study quality is limited by small sample sizes, high dropout rates, variable products used, and industry funding. Valerian is unlikely to be effective for severe insomnia.

Anxiety and Stress

Valerian has been promoted for reducing daytime anxiety and stress, and its mechanism of action through GABA-A receptor modulation provides biological plausibility [22]. However, any potential benefit appears to be modest at best.

Andreatini et al., 2002 (n=36): A randomized, placebo-controlled pilot study evaluated valepotriates (a valerian component) for generalized anxiety disorder [51]. Thirty-six participants received 600 mg/day valepotriate extract, 10 mg/day diazepam (Valium), or placebo for four weeks. The study failed to find statistically significant differences in overall anxiety between groups but suggested valerian may have a potential effect specifically in reducing psychic symptoms of anxiety (mental agitation).

Kennedy et al., 2006 (valerian/lemon balm combination): Tested 120 mg, 240 mg, or 360 mg of valerian extract three times daily combined with lemon balm [52]. The lowest dose (120 mg three times daily) decreased anxiety during stress tests, but the highest dose (360 mg three times daily) paradoxically increased anxiety. Cognitive function decreased with all three dose levels — a concerning finding.

Preclinical evidence: Valerenic acid modulates GABA-A receptors in animal models. A 2014 study showed valerenic acid content correlates with anxiolytic activity in mouse models [53]. Felgentreff et al. (2012) found VA may reduce anxiety while AVA blocks this effect [23].

Synthesis: The evidence for valerian as an anxiolytic is limited to small pilot studies. The dose-response finding where higher doses increased anxiety is notable. Larger RCTs are needed before valerian can be recommended for anxiety.

Restless Legs Syndrome

There is no good evidence that valerian decreases the severity of restless legs syndrome (RLS) symptoms.

Cuellar and Ratcliffe, 2009 (n=37): A clinical trial involving 37 men and women (average age 49) with moderate to severe RLS found that 800 mg of valerian root (providing 1.16 mg total valerenic acid) daily did not significantly reduce RLS severity compared to placebo [54].

The American Academy of Sleep Medicine 2024 guidelines explicitly recommend against the use of valerian for RLS due to lack of evidence [55].

Menopausal Hot Flashes

Mirabi and Mojab, 2013 (n=100): A double-blind RCT with 100 menopausal women found that 2.5 mg of valerian extract twice daily for eight weeks significantly reduced hot flash frequency and severity compared to placebo [56]. This is a single trial with a low dose, requiring replication.

Other Traditional Uses

Valerian has been used for gastrointestinal spasms, epileptic seizures, and ADHD, but scientific evidence is insufficient for these conditions [10][11]. In Ayurvedic medicine, the related species Valeriana wallichii (Tagara) is used for anxiety and sleep [57]. In traditional Chinese medicine, valerian (Xie Cao) is used for digestive spasms [58]. No robust clinical trials support valerian for ADHD or pain [10].

Recommended Dosing

Dosing by Indication

For insomnia (primary use):

• Standardized extract: 300-900 mg, taken 30 minutes to 2 hours before bedtime [10][30][46]. The most commonly studied dose is 600 mg. A dose of 600 mg standardized to 0.4-0.8% valerenic acids provides roughly 2-5 mg of valerenic acids.
• Root powder (non-extract): 2,000-3,000 mg before bed, yielding approximately 2-5 mg valerenic acids [10].
• Duration: Benefits may take several weeks to develop. The Vorbach 1996 trial showed improvement between day 14 and day 28 [30]. Plan on at least 2-4 weeks of consistent use.

For anxiety (speculative):

• 120-240 mg of valerian extract, two to three times daily [52]. Higher doses (360 mg three times daily) paradoxically increased anxiety in one study. The anti-anxiety indication is not well established.

Valerenic Acid Targets

The clinically studied range for valerenic acid intake is approximately 2-5 mg per day:

Product Type	Total Dose	Expected Valerenic Acids
Extract standardized to 0.8%	450-600 mg	3.6-4.8 mg
Extract standardized to 0.4%	600-900 mg	2.4-3.6 mg
Root powder (0.1% VA)	2,000-3,000 mg	2-3 mg
Tea (2-3 g dried root)	2,000-3,000 mg	0.14-2+ mg (highly variable)

How to Read a Supplement Label

Consumers should verify the following on valerian product labels (all required by FDA) [10]:

• Species: Valeriana officinalis
• Plant part: Root (may also state rhizome)
• Form: Root powder, extract, or tincture
• Amount per dose: In milligrams (mg) or grams (g)
• Valerenic acid content (preferable): Look for standardization claims (e.g., "standardized to 0.8% valerenic acids")

Comparison with Evidence-Based Sleep Alternatives

For those seeking evidence-based sleep support, other compounds have stronger clinical evidence than valerian. Melatonin (0.3-0.5 mg) has a well-established mechanism for circadian rhythm regulation. Magnesium glycinate (250-300 mg elemental) reduces sleep onset latency by approximately 17 minutes in meta-analyses. Glycine (2,500-3,000 mg) has demonstrated improved subjective sleep quality in three RCTs.

Dr Brad Stanfield's Sleep by Dr Brad combines these three evidence-based ingredients: micro-dose melatonin (300 mcg), magnesium glycinate (126 mg elemental), and glycine (2,500 mg) — targeting different sleep mechanisms with stronger clinical support than valerian alone.

Safety and Side Effects

General Safety Profile

Single-ingredient valerian products made from Valeriana officinalis are generally considered very safe at recommended doses [10][18]. In most clinical studies, few side effects have been observed beyond occasional, minor gastrointestinal symptoms or allergic reactions. Acute toxicity is low, with oral LD50 values exceeding 15 g/kg in rats for essential oil and over 96 g/kg in mice for aqueous extracts [60]. Recent 2024 studies confirm no genotoxicity [61].

Reported Adverse Effects

Common (mild): Headache, dizziness, gastrointestinal disturbances (nausea, stomach discomfort), pruritus (itching), and vivid dreams [62]. In clinical trials, rates of these effects were similar between valerian and placebo groups [33][45].

Uncommon/Anecdotal: Paradoxical stimulant effect — headache, restlessness, or pupil dilation — poorly documented and based largely on anecdotal evidence [10].

Next-morning effects: A 900 mg dose produced increased next-morning sleepiness [45], but the standard 600 mg dose (LI 156) did not significantly affect reaction time, alertness, or concentration the morning after (Kuhlmann et al., Pharmacopsychiatry, 1999) [63]. Valerian does not generally cause drowsiness upon waking at standard doses [10].

Mental function: Most studies show no adverse effect at standard doses [10][63]. However, the Kennedy 2006 study found cognitive function decreased with all three dose levels of a valerian/lemon balm combination [52]. One study found slightly impaired attention immediately after use, suggesting it may be unsafe to drive or operate machinery within six to eight hours [10].

Valepotriate Safety

Valepotriates showed cytotoxic activity in vitro but were not carcinogenic in animal studies [64][65][66][67]. They are unstable and may not be present in significant amounts in commercial products. Species of valerian other than V. officinalis may contain excessive levels of valtrate [10].

Hepatotoxicity

Hepatotoxicity is rare and primarily associated with combination products rather than single-ingredient valerian. Reports of liver toxicity with valerian-skullcap combinations may have been due to inadvertent substitution of the liver-toxic herb germander in place of skullcap [10][68]. Kava kava, also found in some valerian combinations, has shown potential liver toxicity [10]. Patients with pre-existing liver disease should use caution [70].

Withdrawal and Dependency

Clinical studies have not found withdrawal symptoms upon discontinuation [10]. However, one case report described cardiac complications and delirium associated with valerian withdrawal after long-term, high-dose use (Garges et al., JAMA, 1998) [71]. Long-term use may carry a mild risk of dependency [2]. It may be prudent to taper doses gradually after extended use [10].

Overdose

Overdose symptoms can include tremors, mydriasis, fatigue, and abdominal cramps — uncommon and generally self-limiting within 24 hours [72]. One suicide attempt with massive overdose did not permit clear attribution of symptoms to valerian (Willey et al., 1995) [73].

Special Populations

• Pregnancy/nursing: Safety not well evaluated. Avoid during pregnancy due to potential fetal cytotoxicity and maternal hepatotoxicity risks [74][75].
• Children: Children under 3 should not take valerian [74]. Safety data for older children are limited.
• Pre-surgical: Discontinue at least 2 weeks before surgery to minimize anesthetic interactions and withdrawal risks [70][76].

Drug Interactions

Additive Sedation (Primary Concern)

Valerian may have additive effects with other CNS depressants due to its GABA modulation mechanism [10][11][77]:

Drug/Substance	Examples	Risk
Benzodiazepines	Alprazolam (Xanax), diazepam (Valium), lorazepam (Ativan), triazolam (Halcion)	Additive sedation and drowsiness [11][77]
Barbiturates and CNS depressants	Phenobarbital (Luminal), morphine, propofol (Diprivan)	Enhanced CNS depression [11][77]
Alcohol	—	Compounded sedation; moderate interaction [10][78]
General anesthetics	Various	May prolong emergence from anesthesia [70][76]
Sedative supplements	St. John's wort, kava, melatonin	Additive sedative effects [77]

Valerian should not be taken in combination with benzodiazepines, barbiturates, or alcohol [10].

Pharmacokinetic Interactions (CYP450)

In vitro evidence suggests valerian extracts can inhibit CYP3A4-mediated metabolism [79]. However, a human study by Donovan et al. (2004) found that multiple night-time doses of valerian had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity, indicating minimal clinical relevance [80].

Regulatory Guidance

The European Medicines Agency emphasizes caution with CNS depressants, noting valerian's mild sedative action may enhance their effects. No formal contraindications beyond hypersensitivity are specified in the 2016 herbal monograph [78]. No major food interactions identified apart from alcohol [78].

Laboratory Tests

Valerian has not been reported to influence laboratory tests, though this has not been rigorously studied [3][74][77].

Dietary Sources

Valerian is not a nutrient obtained from the diet in the way that vitamins and minerals are. It is strictly an herbal supplement derived from the roots and rhizomes of the Valeriana officinalis plant.

Plant Distribution and Habitat

Valeriana officinalis is native to Europe and temperate regions of Asia, spanning the British Isles, Scandinavia, Central Europe, and extending eastward to the Caucasus and northwestern Iran [81][82]. It was introduced to North America by European colonists in the 17th-18th centuries and has since naturalized across much of the northern United States and Canada [82][83].

The plant prefers moist, fertile, well-drained soils in damp meadows, woodlands, riverbanks, and stream banks. It tolerates temperatures down to -34 degrees C (USDA Zone 4) and can grow at altitudes up to approximately 2,000 meters [82][84].

Harvesting and Preparation

For medicinal use, roots and rhizomes are harvested in late autumn from second-year or older plants, when valerenic acid concentrations peak [35][36]. Dried roots are processed into powder, extracts, tinctures, and teas. Traditional preparations included infusions of 1-2 grams of dried root daily [85].

Traditional Use in Other Medicine Systems

• Ayurvedic: Valeriana wallichii (Tagara) for anxiety, calmness, and sleep [57]
• Traditional Chinese Medicine: Xie Cao for digestive spasms and Qi flow [58]
• Native American: Root teas for anxiety and sleep (e.g., Blackfoot tribe) [59]

Mechanisms of Action

Valerian's pharmacological effects arise from multiple mechanisms, none fully understood. It is likely that no single active compound is responsible and that effects result from multiple constituents acting synergistically [12][13][14].

GABA System Modulation

Valerenic acid as allosteric modulator: VA potentiates GABA-A receptors containing beta-2 or beta-3 subunits, potentially binding near the loreclezole site to enhance inhibitory neurotransmission [22]. This is similar but not identical to the benzodiazepine mechanism and may contribute to anxiolytic properties without full sedative side effects.

GABA release and reuptake inhibition: In vitro studies suggest valerian extract causes GABA release from nerve endings and blocks its reuptake, increasing synaptic GABA availability [86].

GABA degradation inhibition: Valerenic acid inhibits an enzyme that destroys GABA, further increasing GABA levels [87].

Direct GABA content: Valerian extracts contain GABA, but whether it crosses the blood-brain barrier is uncertain. Glutamine in aqueous extracts may cross the barrier and convert to GABA [28].

Other Pathways

Volatile oils including valerenic acid derivatives demonstrate CNS depressant activity in animal studies [13][21]. However, extracts with very little valerenic acid still show sedative properties, suggesting other components contribute [88]. Valepotriates are active as sedatives in vivo but are too unstable for reliable clinical effect [12][20][89].

Levels of bioactive constituents vary significantly by harvest timing, resulting in marked variability across preparations — one reason why clinical trial results have been inconsistent [90].

References

1. Wichtl M, ed. "Valerianae radix." In: Bisset NG, trans-ed. Herbal Drugs and Phytopharmaceuticals. CRC Press, 1994: 513-516.

2. Schulz V, Hansel R, Tyler VE. "Valerian." In: Rational Phytotherapy. 3rd ed. Springer, 1998: 73-81.

3. Blumenthal M, Goldberg A, Brinckmann J, eds. "Valerian root." In: Herbal Medicine: Expanded Commission E Monographs. Integrative Medicine Communications, 2000: 394-400.

4. Turner W. "Of Valerianae." In: A New Herbal, Parts II and III. Cambridge University Press, 1995.

5. Davidson JRT, Connor KM. "Valerian." In: Herbs for the Mind. Guilford Press, 2000: 214-233.

6. Grieve M. "Valerian." In: A Modern Herbal. Hafner Press, 1974: 824-830.

7. Culpeper N. "Garden valerian." In: Culpeper's Complete Herbal. W. Foulsham, 1994: 295-297.

8. Pereira J. "Valeriana officinalis: common valerian." In: The Elements of Materia Medica and Therapeutics. 3rd ed. 1854: 609-616.

9. Grieve M. A Modern Herbal. 1974 (WWII usage).

10. ConsumerLab. "Valerian Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/valerian-supplements-review/valerian/

11. NIH Office of Dietary Supplements. "Valerian — Health Professional Fact Sheet." Updated March 15, 2013. https://ods.od.nih.gov/factsheets/Valerian-HealthProfessional/

12. Houghton PJ. "The scientific basis for the reputed activity of valerian." J Pharm Pharmacol. 1999;51:505-512. https://pubmed.ncbi.nlm.nih.gov/10411208/

13. Hendriks H, et al. "Pharmacological screening of valerenal and other components of essential oil of Valeriana officinalis." Planta Med. 1981;42:62-68. https://pubmed.ncbi.nlm.nih.gov/17401875/

14. Russo EB. "Valerian." In: Handbook of Psychotropic Herbs. Haworth Press, 2001: 95-106.

15. Taibi DM, et al. "A systematic review of valerian as a sleep aid: safe but not effective." Sleep Med Rev. 2007;11(3):209-230. https://pubmed.ncbi.nlm.nih.gov/17517355/

16. Stevinson C, Ernst E. "Valerian for insomnia: a systematic review of randomized clinical trials." Sleep Med. 2000;1:91-99. https://pubmed.ncbi.nlm.nih.gov/11040461/

17. Bent S, et al. "Valerian for sleep: a systematic review and meta-analysis." Am J Med. 2006;119(12):1005-1012. https://pubmed.ncbi.nlm.nih.gov/17145239/

18. European Medicines Agency. "EU herbal monograph on Valeriana officinalis L., radix." 2016.

19. Bos R, et al. "Analytical aspects of phytotherapeutic valerian preparations." Phytochem Anal. 1996;7:143-151.

20. European Scientific Cooperative on Phytotherapy. "Valerianae radix." ESCOP Monographs, 1997: 1-10.

21. Hendriks H, et al. "Central nervous depressant activity of valerenic acid in the mouse." Planta Med. 1985;1:28-31. https://pubmed.ncbi.nlm.nih.gov/17340433/

22. Benke D, et al. "GABA-A receptors as in vivo substrate for the anxiolytic action of valerenic acid." Neuropharmacology. 2009;56(1):174-181. https://pubmed.ncbi.nlm.nih.gov/18602406/

23. Felgentreff F, et al. "Valerian extract characterized by high valerenic acid demonstrates anxiolytic activity." Phytomedicine. 2012;19(13):1216-1222. https://pubmed.ncbi.nlm.nih.gov/22981945/

24. Bos R, et al. "Cytotoxic potential of valerian constituents." Phytomedicine. 1998;5:219-225.

25. Grokipedia. "Valerian (herb)." https://grokipedia.com/page/Valerian_(herb)

26. Morazzoni P, Bombardelli E. "Valeriana officinalis: traditional use and recent evaluation." Fitoterapia. 1995;66:99-112.

27. Cavadas C, et al. "In vitro study on the interaction of Valeriana officinalis extracts on GABAA receptor." Arzneimittel-Forschung. 1995;45:753-755. https://pubmed.ncbi.nlm.nih.gov/7575738/

28. Santos MS, et al. "An aqueous extract of valerian influences GABA transport in synaptosomes." Planta Med. 1994;60:278-279. https://pubmed.ncbi.nlm.nih.gov/8073095/

29. Grokipedia. "Valerian (herb)." GC-MS profiling data.

30. Vorbach EU, et al. "Treatment of insomnia: effectiveness and tolerance of a valerian extract." Psychopharmakotherapie. 1996;3:109-115.

31. Dorn M. "Valerian versus oxazepam." Forschende Komplementarmedizin. 2000;7:79-84. https://pubmed.ncbi.nlm.nih.gov/10899744/

32. Leathwood PD, et al. "Aqueous extract of valerian root improves sleep quality in man." Pharmacol Biochem Behav. 1982;17:65-71. https://pubmed.ncbi.nlm.nih.gov/7122729/

33. Donath F, et al. "Critical evaluation of the effect of valerian extract on sleep structure." Pharmacopsychiatry. 2000;33:47-53. https://pubmed.ncbi.nlm.nih.gov/10761819/

34. Lefebvre T, et al. "A comparative analysis of three valerian root teas." J Pharm Pharmaceut Sci. 2004;7(2):5-10.

35. Bos R, et al. "Seasonal variation of the essential oil, valerenic acid and derivatives." Planta Med. 1998;64:143-147. https://pubmed.ncbi.nlm.nih.gov/9525106/

36-41. Grokipedia. "Valerian (herb)." Various sections. https://grokipedia.com/page/Valerian_(herb)

42. Leathwood PD, et al. "Aqueous extract of valerian root improves sleep quality in man." Pharmacol Biochem Behav. 1982;17:65-71. https://pubmed.ncbi.nlm.nih.gov/7122729/

43. Shinjyo N, et al. "Valerian root in treating sleep problems — a systematic review." J Evid Based Integr Med. 2020. https://pubmed.ncbi.nlm.nih.gov/33086877/

44. 2024 umbrella review of 8 systematic reviews, 15,000+ participants.

45. Leathwood PD, Chauffard F. "Aqueous extract of valerian reduces latency to fall asleep." Planta Med. 1985;2:144-148. https://pubmed.ncbi.nlm.nih.gov/17340482/

46. Shekhar HS, et al. "Efficacy and safety of valerian root extract for improving sleep." Adv Ther. 2023.

47. Shekhar HS, et al. "Follow-up analysis of valerian root extract for sleep." Adv Complement Alt Med. 2024.

48. Bliwise DL, et al. "Valerian in Parkinson's disease." SLEEP 2007, Abstract Supplement, page A41.

49. Taavoni S, et al. "Valerian/lemon balm use for sleep disorders during menopause." Menopause. 2011;18(9):951-955.

50. Shekhar HS, et al. "Standardized extract of Valeriana officinalis improves overall sleep quality." 2023.

51. Andreatini R, et al. "Effect of valepotriates in generalized anxiety disorder." Phytother Res. 2002;16(7):650-654. https://pubmed.ncbi.nlm.nih.gov/12410546/

52. Kennedy DO, et al. "Anxiolytic effects of Melissa officinalis and Valeriana officinalis." Phytother Res. 2006;20(2):96-102. https://pubmed.ncbi.nlm.nih.gov/16444660/

53. Felgentreff F, et al. "The anxiolytic effects of a Valerian extract is based on valerenic acid." Phytomedicine. 2014.

54. Cuellar NG, Ratcliffe SJ. "Does valerian improve symptoms in people with restless legs syndrome?" Altern Ther Health Med. 2009;15(2):22-28. https://pubmed.ncbi.nlm.nih.gov/19284179/

55. Winkelman JW, et al. "Treatment of restless legs syndrome: AASM clinical practice guideline." J Clin Sleep Med. 2024.

56. Mirabi P, Mojab F. "The effects of valerian root on hot flashes in menopausal women." Iran J Pharm Res. 2013;12(1):217-222. https://pubmed.ncbi.nlm.nih.gov/24250592/

57-59. Grokipedia. "Valerian (herb)." Traditional medicine systems. https://grokipedia.com/page/Valerian_(herb)

60-62. Grokipedia. "Valerian (herb)." Safety and toxicity data. https://grokipedia.com/page/Valerian_(herb)

63. Kuhlmann J, et al. "The influence of valerian treatment on reaction time, alertness and concentration." Pharmacopsychiatry. 1999;32:235-241. https://pubmed.ncbi.nlm.nih.gov/10599933/

64. Bounthanh C, et al. "Valepotriates, a new class of cytotoxic and antitumor agents." Planta Med. 1981;41:21-28. https://pubmed.ncbi.nlm.nih.gov/17401842/

65. Bounthanh C, et al. "The action of valepotriates on the synthesis of DNA and proteins." J Med Plant Res. 1983;49:138-142. https://pubmed.ncbi.nlm.nih.gov/6655405/

66. Tufik S, et al. "Effects of prolonged administration of valepotriates in rats." J Ethnopharmacol. 1996;41:39-44. https://pubmed.ncbi.nlm.nih.gov/7689727/

67. Bos R, et al. "Cytotoxic potential of valerian constituents." Phytomedicine. 1998;5:219-225.

68. MacGregor FB, et al. "Hepatotoxicity of herbal remedies." BMJ. 1989;299:1156-1157. https://pubmed.ncbi.nlm.nih.gov/2513023/

69-70. Grokipedia. "Valerian (herb)." Hepatotoxicity and contraindications. https://grokipedia.com/page/Valerian_(herb)

71. Garges HP, et al. "Cardiac complications and delirium associated with valerian root withdrawal." JAMA. 1998;280:1566-1567. https://pubmed.ncbi.nlm.nih.gov/9820253/

72. Grokipedia. "Valerian (herb)." Overdose symptoms. https://grokipedia.com/page/Valerian_(herb)

73. Willey LB, et al. "Valerian overdose: a case report." Vet Hum Toxicol. 1995;37:364-365. https://pubmed.ncbi.nlm.nih.gov/8540239/

74. ESCOP. "Valerianae radix." Monographs, 1997: 1-10.

75. Grokipedia. "Valerian (herb)." Pregnancy safety. https://grokipedia.com/page/Valerian_(herb)

76. Ang-Lee MK, et al. "Herbal medicines and perioperative care." JAMA. 2001;286(2):208-216. https://pubmed.ncbi.nlm.nih.gov/11448284/

77. Natural Medicines Comprehensive Database. "Valerian." 2013.

78. European Medicines Agency. "EU herbal monograph on Valeriana officinalis L., radix." 2016.

79. Grokipedia. "Valerian (herb)." CYP3A4 inhibition. https://grokipedia.com/page/Valerian_(herb)

80. Donovan JL, et al. "Multiple night-time doses of valerian had minimal effects on CYP3A4 activity." Drug Metab Dispos. 2004;32(12):1333-1336. https://pubmed.ncbi.nlm.nih.gov/15383486/

81. Wichtl M, ed. Herbal Drugs and Phytopharmaceuticals. 1994: 513-516.

82-85. Grokipedia. "Valerian (herb)." Distribution, habitat, and traditional preparations. https://grokipedia.com/page/Valerian_(herb)

86. Santos MS, et al. "An aqueous extract of valerian influences GABA transport in synaptosomes." Planta Med. 1994;60:278-279. https://pubmed.ncbi.nlm.nih.gov/8073095/

87. Morazzoni P, Bombardelli E. "Valeriana officinalis: traditional use and recent evaluation." Fitoterapia. 1995;66:99-112.

88. Krieglstein VJ, Grusla D. "Central depressing components in Valerian." Deutsche Apotheker Zeitung. 1988;128:2041-2046.

89. Hendriks H, et al. "Pharmacological screening of valerenal and other components." Planta Med. 1981;42:62-68.

90. Bos R, et al. "Seasonal variation of the essential oil, valerenic acid and derivatives." Planta Med. 1998;64:143-147. https://pubmed.ncbi.nlm.nih.gov/9525106/